

CorMedix Inc.  
Form 8-K  
December 17, 2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 17, 2010

CORMEDIX INC.

(Exact name of registrant as specified in its charter)

|   |  |  |
|---|--|--|
| Delaware<br>(State or other jurisdiction<br>of incorporation)                           | 001-34673<br>(Commission<br>File Number) | 20-5894890<br>(IRS Employer<br>Identification No.) |
| 745 Rt. 202-206, Suite 303, Bridgewater, NJ<br>(Address of principal executive offices) |  | 08807<br>(Zip Code)                                |

Registrant's telephone number, including area code: (908) 517-9500

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;  
5.02.      Compensatory Arrangements of Certain Officers.

On December 17, 2010, Russell H. Ellison, M.D., M.Sc. resigned from the Board of Directors of CorMedix Inc. and from his position as Chairman of the Board in order to dedicate his full time and efforts to serving as the Chief Executive Officer of Ventrus BioSciences Inc., which commenced trading on the Nasdaq Capital Market on December 17, 2010 in connection with its initial public offering of its common stock.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

December 17, 2010

CORMEDIX INC.

|        |                |                         |
|--------|----------------|-------------------------|
| By:    | /s/ Brian Lenz |                         |
| Name:  |                | Brian Lenz              |
| Title: |                | Chief Financial Officer |